The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.
|FY, 2014||FY, 2015||FY, 2016|
|$68.7 m||$24.6 m||$9.3 m|
Revenue growth, %
|$17.6 m||$21 m|
Operating expense total
|$80.2 m||$44.1 m||$34.5 m|
|($11.5 m)||($19.5 m)||($25.2 m)|
|($11 m)||($19.1 m)||($25.4 m)|
Operating cash flow
|$13.4 m||($29.1 m)||$5 m|